KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Exchange Rate Effect: 2010-2025

Historic Exchange Rate Effect for Emergent BioSolutions (EBS) over the last 14 years, with Sep 2025 value amounting to -$200,000.

  • Emergent BioSolutions' Exchange Rate Effect was N/A to -$200,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.4 million, marking a year-over-year change of. This contributed to the annual value of -$1.2 million for FY2023, which is 340.00% down from last year.
  • As of Q3 2025, Emergent BioSolutions' Exchange Rate Effect stood at -$200,000, which was down 120.00% from $1.0 million recorded in Q2 2025.
  • Emergent BioSolutions' Exchange Rate Effect's 5-year high stood at $1.1 million during Q4 2022, with a 5-year trough of -$1.5 million in Q4 2023.
  • Over the past 2 years, Emergent BioSolutions' median Exchange Rate Effect value was -$200,000 (recorded in 2025), while the average stood at -$157,143.
  • In the last 5 years, Emergent BioSolutions' Exchange Rate Effect plummeted by 400.00% in 2021 and then soared by 250.00% in 2022.
  • Quarterly analysis of 4 years shows Emergent BioSolutions' Exchange Rate Effect stood at -$200,000 in 2021, then slumped by 400.00% to $1.1 million in 2022, then crashed by 236.36% to -$1.5 million in 2023, then reached -$200,000 in 2025.
  • Its Exchange Rate Effect stands at -$200,000 for Q3 2025, versus $1.0 million for Q2 2025 and -$700,000 for Q1 2025.